Latest Breaking News On - Etripamil nasal spray - Page 1 : comparemela.com

Clinical trial finds nasal spray safely treats recurrent abnormal heart rhythms

Clinical trial finds nasal spray safely treats recurrent abnormal heart rhythms
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesJames ipJamese ipPresbyterian weill cornell medical centerJournal of the american college cardiologyMilestone pharmaceuticalsWeill cornell medicineAmerican collegeWeill cornell medical centerEtripamil nasal spray

Milestone Pharmaceuticals : Corporate Presentation -March 28, 2024 at 08:38 am EDT

Company Overview March 28, 2024 Forward Looking Statement The Presentation contains forward-looking statements within.

United statesMilestone pharmaceuticalsAmerican heart associationEmergency departmentCompany overviewExchange commissionMilestone pharmaceuticals data on fileBlueprint research groupPrivate securities litigation reform actQuarterly reportGive patients controlCommon heartEtripamil nasal spraySuccessful phasePositive phaseScience presentation

Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

Milestone Pharmaceuticals Inc. recently announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) compared to placebo. The findings were presented during the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA.

City ofUnited kingdomUnited statesOlmsted countyA john cammDavid bharuchaCardiology clinical academic groupMilestone pharmaceuticals incClinical sciences research instituteDuring the american heart association scientific sessionsMilestone pharmaceuticalsAmerican heart association council on epidemiologyGeorge university of londonPrevention statistics committeeA report from the american heart associationDrug administration

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate compared to.

United kingdomCity ofUnited statesOlmsted countyIsrael generalDavid bharuchaA john cammKim foxPrevention statistics committeeClinical sciences research instituteCardiology clinical academic groupMilestone pharmaceuticalsGeorge universityAmerican heart association council on epidemiologyDrug administrationExchange commission

Etripamil Nasal Spray Outperforms Placebo for AFib with Rapid Ventricular Rate

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

United kingdomUnited statesCity ofA john cammAmerican heart association scientific sessionsClinical sciences research instituteCardiology clinical academic groupMilestone pharmaceuticals incMilestone pharmaceuticalsGeorge universityBritish heart foundation emeritus professorClinical cardiologyRevera phaseEtripamil nasal sprayNasal spray for afibAtrial fibrillation